19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Serum sickness-like reaction associated with cefazolin

      research-article
      1 , , 2 , 2
      BMC Clinical Pharmacology
      BioMed Central

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Although rare, serum sickness-like reactions have been documented to occur following the administration of many antibiotics. Cefazolin, a first generation cephalosporin, is a commonly prescribed antibiotic which is considered to be generally safe and well tolerated. There have been no prior reports linking this drug with sickness-like reactions. We report a probable case of serum sickness-like reaction following a single dose of cefazolin.

          Case Presentation

          A 23 year old man with no significant past medical history was admitted to undergo a laparoscopic donor nephrectomy as part of a living-related renal transplant. One gram of intravenous cefazolin was administered perioperatively. The surgery was completed without complication and the remainder of his hospital course was uneventful. Ten days following discharge the patient developed fevers, painful and swollen joints, and a cutaneous eruption overlying his trunk and extremities. There was no evidence of systemic vasculitis. These clinical findings were most consistent with a serum sickness-like reaction. A brief course of corticosteroids and antihistaminergic therapy was initiated, and complete resolution of the patient's symptoms followed. The Naranjo probability scale indicated that this adverse drug event was probable.

          Conclusion

          Serum sickness-like reaction may be associated with cefazolin therapy.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          Minocycline-induced autoimmune syndromes: an overview.

          To increase awareness of minocycline-induced autoimmune syndromes. Review of relevant publications from the American and European literature. Four minocycline-induced syndromes have been described in 82 patients: serum sickness, drug-induced lupus, autoimmune hepatitis, and vasculitis. Aside from sporadic cases of serum sickness, all other syndromes occurred in patients treated for acne. Drug-induced lupus and hepatitis were by far the most common events (66 cases). Except for serum sickness, which presented shortly (mean, 16 days) after minocycline, the autoimmune syndromes manifested after protracted use (mean, 25.3 months). As expected, the patients with acne were young (mean, 19.7 years). The most frequent symptoms were arthralgia, followed by arthritis, fever, and rash (73, 45, 38, and 29 patients, respectively). Serologically, antinuclear antibodies were the most common finding (63 positive of 68 tests); perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA), when assayed, were similarly frequent (20 of 24 tests). Surprisingly, anti-histone antibodies were uncommon, even among patients with drug-induced lupus (4 of 31 tests). The clinical and serological features of the separate syndromes may overlap. The diagnostic value of pANCA, as well as its possible role in minocycline-induced autoimmunity, are discussed. Minocycline has the potential to evoke a variety of clinical and serological autoimmune expressions. The number of published reports may underestimate the frequency of this condition, which should be suspected and investigated in young patients with autoimmune manifestations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cefaclor-associated serum sickness-like disease: eight cases and review of the literature.

            To describe the clinical features of serum sickness-like diseases (SSLD) in cefaclor-treated patients. Analysis of a case series spontaneously reported to Lyons Pharmacovigilance Center. General and hospital practitioners and the French Network of Regional Pharmacovigilance Centers (FNRPC). All reported cases with a possible causative relationship between cefaclor treatment and SSLD. Eight cases of SSLD following cefaclor treatment are described. The clinical features included cutaneous reactions, arthralgias, and moderate hyperthermia. In 50 percent of the patients, hospitalization was required because of incapacitating symptoms. The outcome was benign in all cases following discontinuation of the offending drug. All eight cases were reported in children under five years of age. Among 137 cefaclor-associated drug reactions collected by FNRPC, 27 cases of SSLD have been reported; 23 of these patients were younger than five years of age. A literature survey confirmed the higher reporting of SSLD in children with cefaclor compared with other antibiotics and suggested an incidence of 0.024-0.2 percent of SSLD per drug course of cefaclor. The case reports and epidemiologic studies confirmed the presumed role of age (patients under five years of age) in cefaclor-induced SSLD and the benign outcome despite severe clinical presentations in some reports.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Serum sickness-like reactions.

              A serum sickness-like reaction (SSLR) to drug administration usually consists of cutaneous rash, arthralgia/arthritis, and, often, fever. This entity rarely has been discussed in the dermatologic literature. We describe the case of a 3-year-old girl with urticaria, fever, and arthralgia that appeared 8 days after starting cefaclor therapy for otitis media.
                Bookmark

                Author and article information

                Journal
                BMC Clin Pharmacol
                BMC Clinical Pharmacology
                BioMed Central (London )
                1472-6904
                2006
                23 February 2006
                : 6
                : 3
                Affiliations
                [1 ]Division of Nephrology and Hypertension, New York Presbyterian Hospital – Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
                [2 ]The Rogosin Institute, New York Presbyterian Hospital – Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
                Article
                1472-6904-6-3
                10.1186/1472-6904-6-3
                1397863
                16504095
                9dc50f3b-d6e9-44d8-b864-4dd12fac3c8a
                Copyright © 2006 Brucculeri et al; licensee BioMed Central Ltd.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 October 2005
                : 23 February 2006
                Categories
                Case Report

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article